Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report
May 05
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 06, 2025
DataAggregated Company Financials
Companies567
- 7D1.2%
- 3M-6.6%
- 1Y-7.6%
- YTD-2.4%
Over the last 7 days, the Biotech industry has risen 1.9%, driven by gains from AbbVie of 1.9%. In contrast, the industry has lost 6.9% in the last 12 months. Earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 06 May 2025 | US$957.9b | US$153.9b | -US$24,808,548,995.62 | 19.6x | -38.6x | 6.2x |
| Thu, 03 Apr 2025 | US$777.4b | US$118.6b | -US$37,150,082,180.22 | 22.1x | -20.9x | 6.6x |
| Sat, 01 Mar 2025 | US$838.5b | US$118.9b | -US$37,247,148,694.97 | 17x | -22.5x | 7.1x |
| Mon, 27 Jan 2025 | US$981.2b | US$149.5b | -US$26,320,970,275.68 | 17.2x | -37.3x | 6.6x |
| Wed, 25 Dec 2024 | US$967.2b | US$149.9b | -US$26,389,155,679.45 | 15.4x | -36.7x | 6.5x |
| Fri, 22 Nov 2024 | US$996.8b | US$150.0b | -US$26,773,538,404.28 | 17.1x | -37.2x | 6.6x |
| Sun, 20 Oct 2024 | US$908.0b | US$113.1b | -US$35,950,283,773.02 | 21.7x | -25.3x | 8x |
| Tue, 17 Sep 2024 | US$932.2b | US$113.2b | -US$35,921,970,608.82 | 23.6x | -26x | 8.2x |
| Thu, 15 Aug 2024 | US$874.6b | US$113.2b | -US$36,248,323,495.67 | 21.4x | -24.1x | 7.7x |
| Sat, 13 Jul 2024 | US$1.2t | US$164.5b | -US$28,119,687,665.65 | 29.4x | -42.2x | 7.2x |
| Mon, 10 Jun 2024 | US$1.2t | US$164.5b | -US$26,798,622,131.21 | 28.1x | -43.1x | 7x |
| Wed, 08 May 2024 | US$1.1t | US$163.1b | -US$27,148,218,752.30 | 25.7x | -41.4x | 6.9x |
| Fri, 05 Apr 2024 | US$1.1t | US$164.3b | -US$23,437,244,791.39 | 23.1x | -48.9x | 7x |
| Sun, 03 Mar 2024 | US$1.2t | US$167.9b | -US$21,319,237,627.75 | 15.9x | -56.5x | 7.2x |
| Tue, 30 Jan 2024 | US$1.4t | US$204.7b | -US$22,656,479,710.00 | 18.6x | -63.1x | 7x |
| Thu, 28 Dec 2023 | US$1.4t | US$204.9b | -US$22,182,372,574.00 | 19.7x | -62.7x | 6.8x |
| Sat, 25 Nov 2023 | US$1.2t | US$204.8b | -US$22,015,480,281.00 | 18.6x | -55.7x | 6x |
| Mon, 23 Oct 2023 | US$1.2t | US$207.4b | -US$13,059,770,915.00 | 16.6x | -93.9x | 5.9x |
| Wed, 20 Sep 2023 | US$1.3t | US$207.5b | -US$12,859,428,048.00 | 16.9x | -99.9x | 6.2x |
| Fri, 18 Aug 2023 | US$1.3t | US$207.7b | -US$12,279,921,044.00 | 17.5x | -103.5x | 6.1x |
| Sun, 16 Jul 2023 | US$1.1t | US$186.7b | -US$15,968,283,125.00 | 12.9x | -71.1x | 6.1x |
| Tue, 13 Jun 2023 | US$1.2t | US$186.0b | -US$15,957,784,646.00 | 11.8x | -72.2x | 6.2x |
| Thu, 11 May 2023 | US$1.2t | US$191.8b | -US$11,888,575,254.00 | 14.5x | -97.7x | 6.1x |
| Sat, 08 Apr 2023 | US$1.2t | US$216.8b | -US$5,729,503,829.00 | 14x | -203x | 5.4x |
| Mon, 06 Mar 2023 | US$1.2t | US$199.0b | -US$4,959,714,454.00 | 16.5x | -232.4x | 5.8x |
| Wed, 01 Feb 2023 | US$1.2t | US$203.8b | US$1.8b | 15.1x | 660.3x | 5.7x |
| Fri, 30 Dec 2022 | US$1.1t | US$203.4b | US$1.8b | 14.3x | 646.9x | 5.6x |
| Sun, 27 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.6x | 845.5x | 5.6x |
| Tue, 25 Oct 2022 | US$1.1t | US$206.2b | US$5.3b | 15.8x | 200.9x | 5.2x |
| Thu, 22 Sep 2022 | US$1.0t | US$206.3b | US$5.7b | 14x | 179.3x | 5x |
| Sat, 20 Aug 2022 | US$1.1t | US$206.4b | US$7.3b | 16x | 147.7x | 5.2x |
| Mon, 18 Jul 2022 | US$1.1t | US$211.3b | US$10.6b | 17.2x | 102.8x | 5.2x |
| Wed, 15 Jun 2022 | US$918.0b | US$212.1b | US$10.9b | 14.5x | 84.3x | 4.3x |
| Fri, 13 May 2022 | US$938.1b | US$210.6b | US$12.5b | 12.8x | 75.3x | 4.5x |
Price to Earnings Ratio
75.3x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.9% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 2.16% | |
| Healthcare | -0.22% | |
| Biotech | 1.19% | |
| Biotech | 1.19% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$196.07 | 1.9% +US$6.6b | 20.5% | PE83.5x | |
| SMMT Summit Therapeutics | US$28.02 | 16.2% +US$3.0b | 526.8% | PB60.4x | |
| ALNY Alnylam Pharmaceuticals | US$273.55 | 7.3% +US$2.7b | 80.9% | PS15.2x | |
| EXAS Exact Sciences | US$53.33 | 17.0% +US$1.6b | -15.8% | PS3.6x | |
| VRTX Vertex Pharmaceuticals | US$500.19 | 0.7% +US$951.2m | 24.3% | PS11.7x |
